Physiologic Performance Response to Salbutamol

Individual beta2-adrenergic Performance Response to Salbutamol

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04615611

Enrollment

Registered

2020-11-04

Start date

2020-11-07

Completion date

2021-11-07

Last updated

2020-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This project aims to investigate the individual physiological response to beta2-adrenergic stimulation with salbutamol on performance-related outcomes

Interventions

DRUGsalbutamol

inhalation of salbutamol

DRUGPlacebo

administration of placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* 18 to 45 years of age * Trained individuals with maximal oxygen uptake above 55 mL/kg/min for men and 50 mL/kg/min for women * Body mass index lower than 26

Exclusion criteria

* Allergy towards study drug * Unacceptable side effects of the study drug * Chronic disease deemed by the MD to impose a risk or severely confound the study outcomes * Current smokers * Use of prescription medicine * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Sprint performance	Measured ½ hour after drug administration	Power output during maximal cycling

Secondary

Measure	Time frame	Description
Muscle strength	Measured ½ hour after drug administration	Quadriceps maximal voluntary contraction
Sprint fatigue tolerance	Measured ½ hour after drug administration	Fatigue index during maximal cycling
Cycling endurance performance	Measured ½ hour after drug administration	4-min time trial on bike ergometer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026